
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation and its role in the disease burden of asthma.

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.

Join leading experts in pediatric eosinophilic esophagitis (EoE), Professors Salvatore Oliva, MD, PhD, and André Hörning, MD, as they explore the multifaceted journey of pediatric patients with EoE through a hypothetical patient case, navigating real-world challenges in managing EoE.
Professors Oliva and Hӧrning explore the journey of pediatric patients with EoE through diagnosis, disease progression, and treatment.
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.